Indian Medical Association East Delhi cordially invites you all to interactive recorded live webinar session on topic "Management of COVID-19 and Preparing clinic for upcoming winter and expectation of infectivity rate ".
HIGHLIGHTS OF THE WEBINAR
Module 1 - Treatment options for COVID-19 mild to moderate (use of Favipiravir) & preparing clinic
for upcoming winter and expectation of infectivity rate: Dr Dhiren Gupta
AIM of treatment
●Standard way of treatment of mild to moderate cases
●Use of Favipiravir
●Practical tip- case based approach
●Case 1 - stratifying the case
●Treatment (mild / moderate/ severe)
●Follow-up instructions – clinical targets, red flag and investigations
●Spectrum of COVID-19
●Pathogenesis of the virus – Phases with respect to onset of the symptoms
●In patient vital status of the patient with charts explained
●Case 2 – Day wise status of patient with treatment given
●Further cases were discussed management day wise symptoms, status and management
Lessons learnt
●Faviparavir may not have role in high risk patients
●Better than ivermectin
●Radiological interpretation in important
Role of radiology
●Pulmonary phase
●Corelation with score and severity
●NIH Guidelines and treatment (mild, moderate and severe disease definitions)
Favipiravir
●What is Favipiravir and dosage
●Side effects
●Drug interactions
●Trails supporting Favipiravir
Conclusion
●When to use early antivirals (Favipiravir/Remdesivir)
●When to Shift from Favipiravir to Remdisivir (based radiology and symptoms)
●Management of patient explained with respect to risk, symptoms and radiological staging
●Winters will increase the severity and transmission
Module 2 - Treatment options for COVID-19 moderate to severe (Use of Remdesivir in reducing
Mortality rate): Dr Atul Gogia
●Classification of severity COVID-19
●Key therapeutic classes under evaluation for treatment of COVID-19 (antiviral
and immunomodulator)
●Therapies predicted to provide benefits at different stages in COVID-19
Remdesivir
●Treatment initiation and dosing regimens
●Safety information and warnings for Remdisivir
●Remdisivir Trail
●NIAID ACTT1 – Clinical Status Ordinal Scale
●Efficacy and safety of Remdisivir
●Simple severe study trail explained
●Simple moderate study explained
●Various studies on Remdesivir described
Dexamethasone
●Composition and dosing
●Trails on dexamethasone discussed
●Trail on hydrocortisone use in COVID-19
●NIH/ISDA – Recommendations and guideline to use dexamethasone and other corticosteroids
Plasma therapy
●Passive immunity
●Use of Monoclonal Antibodies, Hyperimmune Immunoglobulins and Convalescent Plasma
●Trails regarding use of Plama therapy discussed
Conclusion
●Remdesivir
●Steroids
●Appropriate patient selection and timing is the key
Module 3 – Question and Answer session
The questions of delegates were discussed in a very interactive and informative session .
We wish you a great learning experience and thank Indian Medical Association East Delhi for hosting this session. We also thank our sponsors Mylan Pharmaceuticals Pvt. Ltd. to make this program possible.
